Novavax, Inc.: Novavax Prepared to Deliver Protein-based Mon

Novavax has developed a protein-based monovalent XBB.1.5 COVID vaccine candidate and is manufacturing at commercial scale with the intent to be in market during the fall vaccination campaignNovavax

Related Keywords

, Johnc Jacobs , Erika Schultz , Ali Chartan , Products Advisory Committee , World Health Organization , Vaccination Program , Novavax Inc , Centers For Disease Control , Linkedin , Prnewswire Novavax Inc , European Medicines Agency , Nasdaq , Exchange Commission , Drug Administration , Vaccine Administration Errors , Related Biological Products Advisory Committee , Chief Executive Officer , Emergency Use Authorization , Coronavirus Disease , Acute Allergic Reactions , Disease Control , Vaccine Effectiveness , Adverse Events , Vaccine Administration , Vaccine Adverse Event Reporting System , Multisystem Inflammatory Syndrome , Fax Number , Telephone Number , Adjuvanted Fact Sheet , Healthcare Providers Administering Vaccine , Vaccination Providers , Fact Sheet , Financial Condition , Annual Report , Quarterly Reports , Novavax , Repared , Eliver , Protein , Ased , Monovalent , Covid , Vaccine , Consistent , Vrbpac , Recommendation , Wall ,